Prediction markets spend big on celebrity campaigns even as Sydney Sweeney and LeBron James ads stir backlash
Source: Fortune
Prediction-market platforms Novig, Polymarket and Kalshi are escalating celebrity-led advertising ahead of major sports seasons, despite public backlash over promotional tactics and gambling concerns. Polymarket and Kalshi, each valued at roughly $20 billion, are seeking engagement growth as sports contracts drive a significant share of platform activity. Legal risk remains material after the Ninth Circuit in August allowed Nevada to enforce state gambling laws against Kalshi's sports-event contracts; a circuit split could bring the federal-versus-state regulatory dispute to the Supreme Court as early as 2027.
Analysis
Celebrity-led acquisition spending is a warning that prediction-market growth may be becoming less organic and more dependent on promotional intensity ahead of peak sports calendars. If customer acquisition costs rise while state-level access is constrained, the private platforms' implied revenue multiples become vulnerable well before any final judicial resolution; the key KPI is whether sports-contract volume remains durable after promotional periods rather than simply spikes around season openers.
Publicly traded sportsbooks are the clearest second-order beneficiaries of adverse state-level outcomes for event-contract platforms, but the read-through is not one-directional. DKNG, FLUT and MGM could regain some high-frequency sports-betting wallet share if contracts are restricted, while simultaneously facing a higher probability that state regulators pursue tougher advertising, responsible-gaming and tax policies across the entire wagering ecosystem. Near term, the issue is primarily sentiment and legal-headline volatility; over 6-18 months, a Supreme Court or congressional outcome determines whether prediction markets become a structurally lower-tax, nationally scalable substitute for state-licensed sportsbooks.
Consensus may overstate the immediate value transfer to incumbents. Users attracted by prediction markets' trading interface, political contracts and potentially different customer demographics may not migrate one-for-one to sportsbooks; instead, enforcement can reduce total engagement and raise compliance costs sector-wide. The more investable signal is a divergence between sports-contract volume and paid-marketing intensity: sustained volume with declining promotional spend would validate a durable competitive threat, whereas rising spend without retention would favor listed incumbents.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Key Decisions for Investors
- No outright position solely on the advertising news; create a legal-event watchlist around DKNG, FLUT and MGM for Ninth Circuit-related enforcement actions, additional appellate rulings, or Supreme Court review acceptance over the next 1-6 months.
- On a confirmed restriction of sports-event contracts in additional large states, consider a 3-6 month long DKNG / short BETZ pair: DKNG has the more direct U.S. online-sports-betting exposure, while the ETF short reduces single-name execution risk. Exit if state regulators pair the action with broad sportsbook marketing or tax proposals.
- For existing DKNG and FLUT longs, treat this as a regulatory-beta risk rather than a clean competitive positive; reduce exposure if management guides to higher promotional intensity, state tax rates rise, or gaming-hold assumptions deteriorate in the next earnings cycle.
- Monitor private-market indicators rather than extrapolating celebrity campaigns: sports-contract volume per active user, promotional-spend trends, state access changes, and any evidence that event-contract users are substituting away from licensed sportsbook deposits. A sustained improvement in those metrics would falsify the incumbent-benefit thesis.
More News
- AI Debt Binge Is Reordering Risk Hierarchy With Emerging Bonds
- Pharvaris at Wells Fargo conference: oral HAE drug gains ground
- UBS CEO flags investor complacency as geopolitical and economic risks mount
- Trump vows to be at centre of US midterms: Republican convention takeaways
- A chip stock jumps 11.7% as AI demand drives a guidance boost
- Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights